ETON PHARMACEUTCIALS INC (ETON)

What ETON PHARMACEUTCIALS INC does

Eton Pharmaceuticals is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The company currently markets ten commercial rare disease products including INCRELEX®, HEMANGEOL®, ALKINDI SPRINKLE®, KHINDIVI™, DESMODA™, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone, while advancing four additional late-stage product candidates. Revenue is generated through product sales, royalties, and licensing arrangements.

Fundamentals

• Price$37.33 as of 2026-07-09 close
• Market cap$1.0B as of 2026-07-10
• 1-year return+128.9% as of 2026-07-09 close
• Net margin-1.7% as of 2026-07-10
• Gross margin+54.8% as of 2026-07-10
• ROE-5.7% as of 2026-07-10
• Debt / equity1.00 as of 2026-07-10
• Revenue growth (YoY)+79.9% as of 2026-07-10
• Revenue CAGR (3y)+55.5% SEC XBRL
• Beta0.91 as of 2026-07-10

Ask why ETON looks like this →

Key risks (from latest filing)

["Dependence on continued FDA approval and commercial success of limited product portfolio with only ten marketed products; any loss of approval or market downturn for key products could materially impact revenue","Competitive pressure in rare disease market from larger pharmaceutical companies with greater resources, and risk of new competitive therapies affecting product market share","Regulatory and intellectual property risks including patent expiration, ability to defend IP against infringement claims, and evolving FDA requirements for public company compliance"]

See ETON's biggest risks from its latest 10-Q →